Nasdaq On Horizon For Psyence Group: Psilocybin Therapeutics Division Forms New Business Combination
Benzinga
NOVEMBER 16, 2023
The duo comprised of clinical-stage natural psilocybin biotech Psyence Group Inc. and special purpose acquisition company Newcourt Acquisition Corp (NASDAQ: NCAC ) announced that the SEC made effective a Form F-4 registration statement for a new business on November 13. Filed by new public company Psyence Biomedical Ltd. ,
Let's personalize your content